Protagonist Therapeutics (PTGX) Misses Q2 EPS by 3c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.68), $0.03 worse than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist